ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 722,49
0,36%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Enliven Therapeutics Inc (ELVN)

  7. Enliven Therapeutics Inc (ELVN) Actualités

ELVN

Enliven Therapeutics (ELVN)

Enliven Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ELVN
DateHeureSourceTitreSymboleSociété
31/05/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
29/05/202422h08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
29/05/202422h06Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ELVNEnliven Therapeutics Inc
29/05/202422h05GlobeNewswire Inc.Enliven Therapeutics to Present at Two Upcoming Investor ConferencesNASDAQ:ELVNEnliven Therapeutics Inc
14/05/202422h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELVNEnliven Therapeutics Inc
14/05/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELVNEnliven Therapeutics Inc
14/05/202422h05GlobeNewswire Inc.Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdateNASDAQ:ELVNEnliven Therapeutics Inc
11/04/202413h55GlobeNewswire Inc.Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid LeukemiaNASDAQ:ELVNEnliven Therapeutics Inc
09/04/202422h05GlobeNewswire Inc.Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of DirectorsNASDAQ:ELVNEnliven Therapeutics Inc
28/03/202421h05GlobeNewswire Inc.Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024NASDAQ:ELVNEnliven Therapeutics Inc
19/03/202413h30GlobeNewswire Inc.Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline UpdatesNASDAQ:ELVNEnliven Therapeutics Inc
14/03/202421h05GlobeNewswire Inc.Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business UpdateNASDAQ:ELVNEnliven Therapeutics Inc
27/02/202422h05GlobeNewswire Inc.Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:ELVNEnliven Therapeutics Inc
21/02/202401h35Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ELVNEnliven Therapeutics Inc
16/02/202422h15Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ELVNEnliven Therapeutics Inc
15/02/202402h53Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ELVNEnliven Therapeutics Inc
09/11/202322h05GlobeNewswire Inc.Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:ELVNEnliven Therapeutics Inc
10/08/202322h05GlobeNewswire Inc.Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:ELVNEnliven Therapeutics Inc
06/07/202322h06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ELVNEnliven Therapeutics Inc
05/07/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELVNEnliven Therapeutics Inc
26/06/202312h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ELVNEnliven Therapeutics Inc
19/05/202322h20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ELVNEnliven Therapeutics Inc
11/05/202322h05GlobeNewswire Inc.Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial ResultsNASDAQ:ELVNEnliven Therapeutics Inc
10/05/202315h46Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ELVNEnliven Therapeutics Inc
21/03/202321h08Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:ELVNEnliven Therapeutics Inc
06/03/202323h19Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ELVNEnliven Therapeutics Inc
06/03/202322h03Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:ELVNEnliven Therapeutics Inc
01/03/202322h57Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ELVNEnliven Therapeutics Inc
23/02/202323h20GlobeNewswire Inc.Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 MillionNASDAQ:ELVNEnliven Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ELVN

Dernières Valeurs Consultées

USOTC
TNSTD
Jade Power (CE)
NASDAQ
VVBVX
Venerable Strategic Bond...
NASDAQ
FIWNTX
High Dividend Equity All...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés